Pandemic influenza A(H1N1)2009 in Morocco: experience of the Mohammed V Military Teaching Hospital, Rabat, 12 June to 24 December 2009

I Lahlou Amine (idr_lahlou@yahoo.com); T Bajjou1, El Rhaffouli1, A Laraqui1, F Hilali1, K Menouar1, K Ennibi2, M Boudlal2, E A Bouaiti3, K Sbai3, M Rbai3, M Hachim2, S Zouhair1

1. University Mohammed V-Souissi, Faculty of Medicine and Pharmacy, Mohammed V Military Teaching Hospital, Biosafety Level 3 and Research Laboratory, Rabat, Morocco
2. University Mohammed V-Souissi, Faculty of Medicine and Pharmacy, Mohammed V Military Teaching Hospital, Department of Internal Medicine, Rabat, Morocco
3. Royal Armed Forces’ Health Services, Division for Health and Safety Surveillance, Rabat, Morocco

On 12 June 2009, Morocco was the first country in North Africa to report a laboratory-confirmed case of influenza A(H1N1)2009 virus infection. This study describes the epidemiological and clinical characteristics of 240 laboratory-confirmed cases among 594 outpatients with influenza-like illness at the Mohammed V Military Teaching Hospital, Rabat, from 12 June to 24 December 2009. Real-time reverse transcription-PCR was used to confirm the infection. The epidemic peaked in weeks 47 to 49 (16 November to 6 December 2009). The mean age of cases was 23 years (standard deviation: 14 years). Cough was the most common symptom in 200 cases (83%), followed by fever (≥38 °C) in 195 (81%). Diarrhoea or vomiting was reported in 12 (5%) patients. None of the cases developed any complications and no deaths occurred during the study period.

Introduction

Following its identification in humans in Mexico and in the United States in April 2009 [1], the pandemic influenza A(H1N1)2009 virus spread worldwide [2]. On 11 June 2009, the World Health Organization (WHO) raised the pandemic alert level from phase 5 to phase 6, officially marking the beginning of the 2009 influenza pandemic [3]. On 12 June 2009, the Division of Epidemiology and Disease Control of the Moroccan Ministry of Health reported the first laboratory-confirmed case of influenza A(H1N1)2009 virus infection in north Africa, in a traveller returning from Canada [4]. Subsequently, the number of laboratory confirmed cases in Morocco rose continuously, and reached a total of 2,890 including 64 deaths by 10 March 2010 [5].

The burden of influenza on the African continent is unclear. This is in part due to a lack of systematic surveillance across the continent, limited testing facilities and the prioritisation of other infectious diseases. Factors, such as health care availability, prevalence of co-morbidities or co-infections, or population age structure could affect the influenza burden specifically for this continent. Data from Africa on the pandemic influenza A(H1N1)2009 is also scarce [6,7]. A comprehensive surveillance from all parts of the world is nevertheless important.

The aim of this study, performed in the Mohammed V Military Teaching Hospital (MVMTH) in Rabat, Morocco, was to investigate the epidemiological and clinical characteristics of the cases of influenza A(H1N1)2009 and to report the laboratory diagnosis data in our hospital during the pandemic from June 2009 to December 2009.

The MVMTH in Rabat, Morocco, is a 1,000 bed university hospital with about 80,000 inpatient admissions and 200,000 outpatients per year. It is intended for active or retired military personnel as well as their families in priority, but it also treats civilians thereby serving about 5 million people living in the north of the country. At the time the pandemic began (12 June 2009), the MVMTH was opened to all the population for influenza diagnosis and treatment. This resulted in a small, yet insignificant, increase in out- and inpatients at the hospital.

Methods

Patients and samples

The study, conducted from 12 June to 24 December 2009, involved 594 outpatients with influenza-like illness (ILI) characterised by at least two of the following symptoms including fever (≥38 °C), cough, muscular pain, headache, rhinorrhoea, dyspnoea, diarrhoea and vomiting. Demographic, clinical and epidemiological data of patients were collected by the medical staff using a questionnaire that was completed when
samples were taken. The items collected on the questionnaire were: age, sex, clinical symptoms, co-morbidities, recent travel history in an epidemic country and vaccination against seasonal influenza.

In the period from 12 June to 28 August (referred to as the pre-epidemic period for this study), in which all the confirmed cases of A(H1N1)2009 were imported, swabs were taken from ILI outpatients and a total of 18 of their contacts. During the period from 29 August to 24 December (here referred to as the epidemic period), in which there were also autochthonous cases with no travel history in an epidemic country, the collection of specimens was restricted to ILI outpatients and for grouped cases, such as members of the same family or of the same school class or cases in the same military barracks, only a representative sample was tested for influenza A(H1N1)2009 virus infection.

Oseltamivir was given to all patients immediately after sampling. The treatment was stopped if patients tested negative for influenza A(H1N1)2009. Patients who were confirmed positive for influenza A(H1N1)2009 continued the treatment (oseltamivir 2x75mg/day for five days) and all their contacts received preventive treatment. The follow-up of patients was documented. At the beginning of the pandemic, a hospital ward with 20 beds was reserved for the treatment and quarantine of influenza patients. As the virulence of the strain was unknown, all suspected cases were maintained in quarantine until they were confirmed. For cases who were positive for influenza A(H1N1)2009, containment was maintained until they recovered. As ILI cases increased from mid-november, these measures were replaced by homecare.

**Laboratory confirmation of infection with influenza A(H1N1)2009 virus**

ILI patients were swabbed and nasopharyngeal swabs from the patients were transported to the biosafety level-3 laboratory in a standard, triple-packaging system following the United Nations (UN) z814 class 6.2 specifications [8]. RNA was extracted from nasopharyngeal swabs using the High Pure Viral RNA Isolation Kit (Roche) and one-step real-time RT-PCR was performed using the RealTime ready Influenza A/H1N1 Detection Set and RealTime ready RNA Virus Master (Roche). A confirmed case was defined as an ILI case whose

**Figure 1**

Patients with influenza-like illness and laboratory-confirmed cases of influenza A(H1N1)2009 virus infections, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=240)

<table>
<thead>
<tr>
<th>Weeks</th>
<th>0</th>
<th>20</th>
<th>40</th>
<th>60</th>
<th>80</th>
<th>100</th>
<th>120</th>
<th>140</th>
<th>160</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>0</td>
<td>20</td>
<td>40</td>
<td>60</td>
<td>80</td>
<td>100</td>
<td>120</td>
<td>140</td>
<td>160</td>
</tr>
</tbody>
</table>

**Table 1**

Characteristics of patients with influenza-like illness and laboratory-confirmed cases of influenza A(H1N1)2009 virus infections, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=594)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total</th>
<th>Patients with influenza-like illness A(H1N1)2009-negative n (%)</th>
<th>Patients with influenza-like illness A(H1N1)2009-positive n (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, N (%)</td>
<td>594</td>
<td>354 (60%)</td>
<td>240 (40%)</td>
<td>0.175</td>
</tr>
<tr>
<td>Number of males, n/N (%)</td>
<td>349 (59%)</td>
<td>200/354 (56%)</td>
<td>149/240 (62%)</td>
<td>0.004</td>
</tr>
<tr>
<td>Mean Age and standard deviation</td>
<td>28±16</td>
<td>31±17</td>
<td>23±14</td>
<td></td>
</tr>
</tbody>
</table>
swab yielded a positive RT-PCR result. Between 12 June and 28 August 2009, in the pre-epidemic phase, 18 contacts of confirmed cases, who did not necessarily present with ILI, were also tested for pandemic influenza A(H1N1)2009 virus infection using the same procedure as above. All the patients considered for this study were tested. We had two inhibited tests: they were repeated using different concentrations (1/2, 1/10, 1/20) and were both positive at the dilution of 1/10.

Statistical analysis
All statistical analysis was carried out using SPSS (release 7.5.1). Normal data distributions were assessed with the Kolmogorov–Smirnov test. Skewed variables were natural log transformed. Patients’ ages were categorised into six groups. Student’s t-test and one-way analysis of variance procedures were used for the comparison of categorical variables between groups. Odds ratios (ORs) and 95% confidence interval (CI) were obtained using the logistic regression model with backward likelihood ratio method. Removal testing is based on the probability of the likelihood-ratio statistic, which is also based on the maximum partial likelihood estimates. For this purpose, all variables were entered and eliminated step by step according to default criteria with a probability for entry and removal of 0.05 and 0.10, respectively. Reference values were age greater than 40 years and an absence of symptoms for all clinical variables. A p value less than 0.05 was considered to be statistically significant.

Results
Of 594 ILI outpatients from 12 June to 24 December 2009, 240 (40%) were laboratory confirmed as cases of influenza A(H1N1)2009 virus infection and 354 (60%) were negative. Between 12 June and 28 August 2009, in the pre-epidemic phase, 18 contacts of confirmed cases, were also tested for pandemic influenza A(H1N1)2009. Ten contacts who were asymptomatic tested positive for pandemic influenza 2009. Contacts presenting with ILI were considered as ILI patients for our analysis.

At the beginning of the outbreak, 27 confirmed cases required a few days of hospitalisation because they had identifiable underlying conditions. These included pregnancy (n=13), asthma (n=7), obesity (n=2) and diabetes mellitus (n=5). All these cases were put under supervision until their full recovery.

A rapid increase in the number of confirmed cases was observed with a peak in weeks 47 to 49 (16 November to 6 December 2009): 172 cases were detected during this time (Figure 1).

At the beginning of the study period, from 12 June to 28 August all cases were imported (n=13, 100%), seven from Spain, two from France, and one respective case from Italy, the Netherlands, Brazil and Canada. In the epidemic period, the proportion of cases with no travel history increased from mid-November 2009, to reach 92% (n=222) by 24 December.

Of the total confirmed cases of influenza A(H1N1)2009 virus infection over the whole study period, 149 (62%) were men (Table 1). There were no differences in the mean age of cases by sex (women: 24±14 years, men: 22±14, p=0.57).

The ages of confirmed cases ranged between three months and 60 years, with a mean of 23 years (standard deviation: 14). The age followed a normal distribution according to the Kolmogorov–Smirnov test. A total of 207 (86%) cases were aged 40 years old and younger and only 5 cases (2%) were aged over 50 years. Compared to the reference group (>40 years), the risk of infection was greater in those aged 14 years old and under (OR: 3.38; 95% CI: 1.99–5.73, p<0.001) and those aged from 14 to 27 years (OR: 2.62; 95% CI: 1.55–4.42, p<0.05) (Table 2, Figure 2).

Table 2. Laboratory-confirmed cases of influenza A(H1N1)2009, and A(H1N1)2009 virus negative patients with influenza-like illness, by age group, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=594)

<table>
<thead>
<tr>
<th>Age of patients in years</th>
<th>Number of A(H1N1)2009-negative cases</th>
<th>Number of A(H1N1)2009-positive cases</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 5</td>
<td>20</td>
<td>18</td>
<td>38 (6)</td>
</tr>
<tr>
<td>&gt;5 to 14</td>
<td>48</td>
<td>65</td>
<td>113 (19)</td>
</tr>
<tr>
<td>&gt;14 to 27</td>
<td>82</td>
<td>72</td>
<td>154 (26)</td>
</tr>
<tr>
<td>&gt;27 to 40</td>
<td>97</td>
<td>52</td>
<td>149 (25)</td>
</tr>
<tr>
<td>&gt;40 to 50</td>
<td>72</td>
<td>28</td>
<td>100 (17)</td>
</tr>
<tr>
<td>&gt;50</td>
<td>35</td>
<td>5</td>
<td>40 (7)</td>
</tr>
<tr>
<td>Total</td>
<td>354</td>
<td>240</td>
<td>594 (100)</td>
</tr>
</tbody>
</table>

Figure 2. Laboratory-confirmed cases of influenza A(H1N1)2009 by sex and age group, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=240)
with influenza-like illness, by age group, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=594)

Fever, cough, headache, muscular pain and rhinorhoea were the main symptoms: cough was the most common (n=200, 82%) followed by fever (n=195, 80%). The ORs were 4.2 (95% CI: 2.51–7.04, p<0.001) and 5.58 (95% CI: 3.43–9.09, p<0.001) for cough and fever respectively. Diarrhoea or vomiting was reported in 12 cases (5%). None of the 240 cases developed any complications and there were no deaths during the study period. Variations of symptoms by age groups were not significant (Table 3).

A total of 238 (99%) cases received antiviral treatment with neuraminidase inhibitors (oseltamivir) immediately after laboratory confirmation of the infection.

Discussion

Morocco was the first country in North Africa to report a laboratory-confirmed case of influenza A(H1N1)2009 virus infection. Here we present a study from Morocco, thereby contributing data from North Africa to the global data and adding to the overview of the A(H1N1)2009 pandemic. The epidemic curve obtained for the hospital outpatients of this study was similar to the epidemic curve for the pandemic in Morocco [5]. In European countries, the pandemic started in weeks 30 to 32, 2009, and the number of confirmed-cases peaked in weeks 38 to 40. Variations of symptoms by age groups were not significant (Table 3).

In weeks 41, 42, and 43, no confirmed case was reported. This can be explained by the fact that, by the end of summer holidays, there was a decline in arrivals of tourists and Moroccans who had spent their holidays abroad. Moreover, the measures taken for containment could also have contributed to the delay of the emergence of secondary cases until the week 44 marking the shift from imported to local cases. The peak of the epidemic was reported on week 49 and then the number of confirmed cases decreased from week 52. This difference with European countries is probably due to the fact that the decline in temperatures settles earlier in Europe than in Morocco and lasts for a longer period. The distribution of the 240 cases of laboratory-confirmed A(H1N1)2009 virus infection by sex and age group was similar to that of cases observed in several European countries which may have a climate almost similar to that of Morocco like Spain [12] or with much cooler winters like Ireland [13]. There was an under-representation of infection in older people and the majority of cases were 40 years and under (86%). It has been shown that schoolchildren play an important role in the spread of influenza A(H1N1)2009 virus [12] and this predominance of infection in young people has been reported by other authors [15-16].

Moreover, several reports of the A(H1N1)2009 pandemic showed that attack rates were higher in children younger than 15 years [16,17]. In addition, a report from Mexico noted that most cases occurred in people younger than 50 years, with 89% of cases of pneumonia [17] and 85% incidence of mortality due to A(H1N1)2009 infection in this age group [18]. The lower frequency of influenza A(H1N1)2009 cases among those over 50 years of age is consistent with other investigations [17,18,19]. This can be explained by the fact that older people may have partial immunity from previous exposure to other influenza A(H1N1) strains [20] or that the

### Table 3

Symptoms by age group of laboratory-confirmed cases of influenza A(H1N1)2009 virus infection, Mohammed V Military Teaching Hospital, Rabat, Morocco, 12 June–24 December 2009 (n=240)

<table>
<thead>
<tr>
<th>Clinical symptoms</th>
<th>Total n (%)</th>
<th>Age of patients in years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 to 5 n (%)</td>
<td>5 to 14 n (%)</td>
</tr>
<tr>
<td>Cough</td>
<td>199 (83)</td>
<td>14 (7)</td>
</tr>
<tr>
<td>Fever</td>
<td>193 (80)</td>
<td>15 (8)</td>
</tr>
<tr>
<td>Muscle pain</td>
<td>122 (51)</td>
<td>6 (5)</td>
</tr>
<tr>
<td>Headache</td>
<td>54 (23)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Rhinorhœa</td>
<td>85 (35)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>5 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhoea, vomiting</td>
<td>12 (5)</td>
<td>2 (17)</td>
</tr>
</tbody>
</table>

Almost 3.5 million Moroccan workers and their families live in Europe and return to Morocco for holidays every summer [11] and in addition approximately eight millions tourists from Europe, Asia and North America visit Morocco each year [11].

In weeks 41, 42, and 43, no confirmed case was reported. This can be explained by the fact that, by the end of summer holidays, there was a decline in arrivals of tourists and Moroccans who had spent their holidays abroad. Moreover, the measures taken for containment could also have contributed to the delay of the emergence of secondary cases until the week 44 marking the shift from imported to local cases. The peak of the epidemic was reported on week 49 and then the number of confirmed cases decreased from week 52. This difference with European countries is probably due to the fact that the decline in temperatures settles earlier in Europe than in Morocco and lasts for a longer period. The distribution of the 240 cases of laboratory-confirmed A(H1N1)2009 virus infection by sex and age group was similar to that of cases observed in several European countries which may have a climate almost similar to that of Morocco like Spain [12] or with much cooler winters like Ireland [13]. There was an under-representation of infection in older people and the majority of cases were 40 years and under (86%). It has been shown that schoolchildren play an important role in the spread of influenza A(H1N1)2009 virus [12] and this predominance of infection in young people has been reported by other authors [15-16].

Moreover, several reports of the A(H1N1)2009 pandemic showed that attack rates were higher in children younger than 15 years [16,17]. In addition, a report from Mexico noted that most cases occurred in people younger than 50 years, with 89% of cases of pneumonia [17] and 85% incidence of mortality due to A(H1N1)2009 infection in this age group [18]. The lower frequency of influenza A(H1N1)2009 cases among those over 50 years of age is consistent with other investigations [17,18,19]. This can be explained by the fact that older people may have partial immunity from previous exposure to other influenza A(H1N1) strains [20] or that the
influenza A(H1N1)2009 virus had not been widely introduced in this subpopulation.

The clinical manifestation of influenza A(H1N1)2009 virus infection in our investigation was similar to that observed for seasonal influenza [14,21,22]. All cases presented predominantly mild and self-limiting illness, with cough and fever being the most common symptoms. The ORs for fever and cough (3.38; 2.62 respectively) were consistent with a literature review by Petrosillo et al. with descriptions of A(H1N1)2009 cases across the world [23]. According to this study, A(H1N1)2009 patients complained mostly of the classical influenza symptoms. In the review from Petrosillo et al., fever was reported by a median of 87% (62–100%) of cases, cough by 82.5% (59–100%) sore throat by 57% (2–52%), diarrhea by 13.5% (2–50%), and vomiting by 12.5% (2–50%). Other reported symptoms included myalgia, arthralgia, nasal-congestion headache, anorexia, nausea and conjunctivitis.

In our study, some cases required a few days of hospitalisation at the beginning of the outbreak because they had identifiable underlying conditions (such as pregnancy, asthma, obesity and diabetes mellitus). It was a precautionary measure given that during this period the pathogenicity of the A(H1N1)2009 virus was still poorly known. All these cases evolved favorably under treatment.

Almost all of the confirmed cases (98%) received early treatment (24 to 48 hours after onset of symptoms) with neuraminidase inhibitors, which may have had a favourable impact on the clinical expression of the infection. Indeed, most of them presented with mild illness and made good progress under specific antiviral treatment and no deaths were recorded. However, in another report from Morocco, the mortality rate was 3.5%. This difference may be explained by the fact that this study included hospitalised cases and severe infections [24] in contrast to the outpatients in this study.

The limitations of our study stem from the fact that it is derived from only one hospital. Also because of the workload of the clinicians during the pandemic period, the questionnaires were not always properly informed, in particular information on co-morbidities. Therefore some data were missing and not exploitable.

The study nevertheless contributed to the epidemiological surveillance of A(H1N1)2009 virus infections (number of cases, deaths, changes over time) during the pandemic and allowed to enrich national and international databases.

Acknowledgements
The authors thank Dr Abdellatif Allami for his help in carrying out statistical analysis in this study.

References


